Maureen Pelletier
8 Papers
Maureen Pelletier is an academic researcher. The author has contributed to research in topics: Internal medicine & Medicine. The author has an hindex of 1, co-authored 5 publications.
Chat about Author
Papers
Molecular characteristics of advanced colorectal cancer and multi-hit PIK3CA mutations.
Michael Cecchini,Ethan Sokol,Neil Vasan,Dean Pavlick,Richard Huang,Maureen Pelletier,Mia A. Levy,Lajos Pusztai,Jill Lacy,Joseph Paul Eder,Janie Yue Zhang,Jeffrey S. Ross +11 more
TL;DR: Double-hit mutations in PIK3CA are seen in 1.7% of advanced CRC patients and may represent a subset of patients that may have enhanced sensitivity to PI3K inhibitors, which is a clinically meaningful prevalence of multi-hit Pik3CA.
2
Targetable genomic mutations in young women with advanced breast cancer.
Norin Ansari,Lucy Gao,Ethan Sokol,Smruthy Sivakumar,Richard Huang,Maureen Pelletier,Mia A. Levy,Dean Pavlick,Natalie Danziger,Jeffrey S. Ross,Maryam B. Lustberg,Mariya Rozenblit +11 more
TL;DR: Findings confirm that young women with breast cancer have actionable genomic alterations (GA) and different mutational profiles may support differential use of targeted and immune therapies.
Metastatic breast cancer (MBC) with ultra-high tumor mutational burden (UHTMB): A comprehensive genomic profiling (CGP) study.
Kristina A. Fanucci,Maryam B. Lustberg,Neal A. Fischbach,Maureen Pelletier,Abirami Sivapiragasam,Prashanth Ashok Kumar,Mansi Kallem,Natalie Danziger,Ethan Sokol,Smruthy Sivakumar,Dean C. Pavlick,Jeffrey S. Ross,Lajos Pusztai +12 more
TL;DR: In this paper , the authors evaluated the genomic landscape of MBC with ultra high TMB, defined at > 20 mutations/Mb, and evaluated all classes of genomic alterations (GA), TMB and microsatellite instability (MSI) and trinucleotide mutational signatures.
Abstract P2-23-09: Ultra-high Tumor Mutation Burden in Metastatic/Clinically Advanced Breast Cancer (MBC)
Kristina A. Fanucci,Maryam B. Lustberg,Neal A. Fischbach,Maureen Pelletier,Abirami Sivapiragasam,Prashanth Ashok Kumar,Mansi Kallem,Natalie Danziger,Ethan Sokol,Smruthy Sivakumar,Dean Pavlick,Jeffrey S. Ross,Lajos Pusztai +12 more
TL;DR: Fanucci et al. as discussed by the authors determined the frequency and genomic landscape of MBC patients with ultra-high tumor mutation burden (UHTMB) defined as a TMB > 20 mutations/Mb, among these 45 (2.2% of all cases) had UHTMB.
The mutational profile of ER-, PR+, HER2- metastatic breast cancer.
Neal A. Fischbach,Richard Huang,Maryam B. Lustberg,Maureen Pelletier,Lajos Pusztai,Smruthy Sivakumar,Ethan Sokol,Jeffrey S. Ross,Mia A. Levy +8 more
TL;DR: The mutational profile for ER-PR+Her2- metastatic breast cancer more closely resembles TNBC than ER+ breast cancer, and molecular profiling may be a useful adjunct to optimize treatment strategies for this rare subset of cancers.